SecukinumabSecukinumab is a human monoclonal antibody directed against the pro-inflammatory interleukin 17 alpha (IL17A). Secukinumab is being used in the treatment of multiple autoimmune diseases.
What can Sanquin do for you?
- Measure drug levels of free drug in the serum using an validated ELISA.
- Measure the immunogenicity of secukinumab.
- Provide assay reagents or co-develop novel testing strategies.
- Folllowing ISO, FDA/EMA, RUO guidelines.
Enquire about our validated drug level and ADA assays by emailing us at [email protected].
In general, reference levels are not provided in the drug insert.
Reference levels established using the Sanquin assay
PSORT publication coming up shortly.
Reference levels from the general literature
Other publications using the Sanquin assay
For an extensive overview of our publications and collaborations, see literature.
Secukinumab background information
Secukinumab is a human monoclonal antibody that targets IL-17A cytokine to downregulate inflammation in psoriasis, an autoimmune dermatological disease. The pathophysiology of psoriasis has not been fully established; however, it is known that dysregulation of innate and adaptive immune responses plays part in the chronic inflammation associated with the disease. IL-17 represents is a six-membered family (IL-17A to F) of pleiotropic pro-inflammatory cytokines, expression of which is found to be elevated in psoriatic skin. These cytokines act on many different cell types and provide defence against different extracellular pathogens causing fungal or bacterial infections. IL-17 cytokines are produced by many cells involved in immune system defence, such as Th17, mast cells, neutrophils, and dendritic cells - all implicated in promoting inflammation. There is evidence linking IL-17 to pathogenesis of multiple autoimmune diseases including rheumatoid arthritis, spondylarthritis, psoriasis, Crohn's disease, multiple sclerosis, and even atherosclerosis.
Currently, there are no biosimilars for secukinumab available on the market.
In Europe, Secukinumab is indicvated for the treatment of:
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Axial spondyloarthritis
- Two types of juvenile idiopathic arthritis, enthestitis-related arthritis and juvenile psoriatic arthritis
Consult CHMP for details.